(Date:12/2/2009)... , SINGAPORE, Dec. 2 S*BIO Pte ...l oral JAK2 inhibitor, SB1518, at The American Soc...ion in New Orleans. ,, Data will be presented o...ation trial of SB1518 detailing its safety, tolera... profile in dose levels ranging from 100 to 600 mg...
(Date:12/2/2009)..., SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The w... are in turmoil and uncertainty is part of many,bu...rma industry has been,relatively immune to the eco...ation. , During the midst of the difficul...n & Johnson inaugurated an R&D center in S...
(Date:12/1/2009)...NCLINE VILLAGE, Nev., Dec. 1 /PRNewswire-FirstCall...day announced revenue guidance for the fourth quar...illion, as compared with $69 million for the fourt... results was the first of two installment payments...fourth quarter 2008 results was a one-time $1.8 mi...
(Date:12/1/2009)...PLYMOUTH, Mass., Dec. 1 Harvest Te... today results from the company sponsored 60-patie...ical Center in Chennai, India using the company,s ...able Critical Limb Ischemia (CLI). Sri Ramachandra...-associated institution based in Chennai, India an...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3...ounces FDA approval of TAXUS(R) Express2(TM) Stent... restenosis, NATICK, Mass., Sept. 25 Boston Scie...hat it has received approval from,the U.S. Food an...,Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary...ighly deliverable drug-eluting stent (DES),specifi...
...Shut Down of Discovery Operations and Expansion of...ities -, LA JOLLA, Calif., Sept. 25 TorreyPines ... that it will transition from a,discovery and deve...using,on its three clinical development programs. ...s through the shut down of its discovery operation...
... Compensation consulting firm plans to r...are designed to identify potential compensation is...San Francisco, CA (PRWEB) September 25, 2008 -- Si...oped various tools to help its consultants more ef...ctures for companies of all sizes. In response to...
Other Biology Technology:Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels 2Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels 3Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels 4TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 2TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 3TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds 4Presidio Pay Advisors Releases Salary GPS Tool 2Random DNA mutagenesis Service from Yorkshire Bioscience Ltd
...ed solution for scheduling, performing and documen...ing for all pipettes and liquid handling devices. ...orts all gravimetric calibration protocols Meets...irements Includes setup information for balances...
...ee plasmid DNA preparations are prepared from cust...1mg to multi-gram scales. Small-scale (1-100mg) a...ons are made according to customer specifications....omer needs, and glycerol stocks are maintained to ...
...ones which belong to the transforming growth facto...arge group of extra-cellular growth factors which ...function and tumor formation (1). Other members in...fferentiation factors, AMH/MIS (Anti-Mullerian Hor...
Biology Products: